Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Y Mukish M Yelanchezian
 -- 1699 2022-06-17 05:06:39 |
2 format corrected.
Beatrix Zheng
 -16 word(s) 1683 2022-06-17 11:52:54 | |
3 typos corrected.
Beatrix Zheng
 Meta information modification 1683 2022-06-20 08:24:20 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
M Yelanchezian, Y.M.; Kwakowsky, A.; Waldvogel, H.; , . The Relationship between Caffeine and Cognition. Encyclopedia. Available online: https://encyclopedia.pub/entry/24141 (accessed on 28 April 2024).
M Yelanchezian YM, Kwakowsky A, Waldvogel H,  . The Relationship between Caffeine and Cognition. Encyclopedia. Available at: https://encyclopedia.pub/entry/24141. Accessed April 28, 2024.
M Yelanchezian, Y Mukish, Andrea Kwakowsky, Henry Waldvogel,  . "The Relationship between Caffeine and Cognition" Encyclopedia, https://encyclopedia.pub/entry/24141 (accessed April 28, 2024).
M Yelanchezian, Y.M., Kwakowsky, A., Waldvogel, H., & , . (2022, June 17). The Relationship between Caffeine and Cognition. In Encyclopedia. https://encyclopedia.pub/entry/24141
M Yelanchezian, Y Mukish, et al. "The Relationship between Caffeine and Cognition." Encyclopedia. Web. 17 June, 2022.
The Relationship between Caffeine and Cognition
Edit
This entry is adapted from the peer-reviewed paper 10.3390/molecules27123737

Caffeine is a natural trimethyl xanthine alkaloid in which the three methyl groups are located at positions 1, 3, and 7 (1,3,7-Trimethylxanthine). Caffeine has high oral bioavailability, with 99% of caffeine being absorbed from the gastrointestinal (GI) tract into the bloodstream 45 min after ingestion. A peak plasma concentration of 1–10 μM (0.25–2 mg/L) reached 15–120 min post oral ingestion from a cup of coffee in humans. Caffeine, a key psychoactive ingredient in coffee, is a short-acting neurostimulator with known neuromodulator effects on the brain by inhibiting phosphodiesterase, mobilizing intracellular calcium, antagonism of adenosine receptors, and modulation of GABA receptor function. Rodent studies have also reported caffeine can inhibit amylogenic-Aβ protein production and improve cognition in rodent AD models. However, results from previous clinical studies were controversial, with some reporting caffeine to be neuroprotective, while others report no effect or even detrimental effects on cognition.

caffeine coffee cognition Alzheimer’s disease dementia

1. Introduction

Alzheimer’s disease (AD) is reported to be the leading cause of dementia and the significant healthcare burden of the 21st century [1]. In 2015, over 46 million people were reported to be living with dementia (costing US 818 billion), a figure projected to reach 131.5 million dementia patients by the year 2050 [2]. Developed countries with an ageing population are expected to be worse hit by this burden. Typical clinical presentation of dementia includes memory impairment and executive function decline that interferes with daily activities making the elderly less independent and forcing them to engage with support services [1]. Atypical presentation of dementia consists of a more pronounced memory deficit causing language, visual, and executive problems [1]. Atypical dementia is more common in early-onset dementia, which is reported to have a strong genetic component [1].
The pathophysiology of AD is based on the accumulation of abnormally folded Aβ and Tau proteins in amyloid plaques and neuronal tangles that contribute to neurodegeneration in patients’ brains [3]. Much of this evidence comes from studying familial AD, where there exist mutations in APP genes, which alter the action of γ-secretases that cleaves Amyloid Precursor Protein (APP), causing an accumulation and aggregation of Aβ peptide [4]. Hyperphosphorylated Tau (PTau) protein, another prerequisite for AD diagnosis, accumulates intracellularly and fibrillates into paired helical filaments that form neurofibrillary tangles [5]. It has been proposed that PTau can further accelerate Aβ dysfunction [5]. A significant genetic factor for AD is APOE mutations, with the lifetime risk of AD being 50% for homozygous APOE4 carriers and 20–30% for APOE3 and APOE4 heterozygous carriers [6]. However, even without an APOE mutation at 85 yr of age, there is an 11–15% risk of developing AD, indicating there might be a significant environmental component to AD [6]. Recent evidence has suggested many lifestyle factors: diabetes, diet, socioeconomic status (SES), education, physical and mental activity, depression, tobacco use, and alcohol intake may affect the chance of developing AD and dementia [7]. The Rotterdam study even demonstrated that eliminating the seven most hazardous risk factors could reduce the incidence of dementia by 30% [8]. In the absence of a definitive clinical treatment currently, eliminating these modifiable risk factors is people's best tool for reducing the burden of dementia and AD.
Coffee, the most heavily consumed caffeinated beverage, has been a popular research topic in AD, with several epidemiological studies positing its neuroprotective effect [9]. Coffee comprises a few independently neuroprotective components: caffeine, chlorogenic acid, caffeic acid, and trigonelline [10]. Chlorogenic acid has been shown to reduce blood-brain barrier (BBB) damage and improve neuronal differentiation in mice [11]. Caffeic acid and phytochemicals in coffee act as antioxidative and anti-inflammatory substances, thereby helping reduce cognitive decline [12]. Trigonelline from coffee beans has been shown to alleviate neuronal loss by reducing oxidative stress, astrocyte activity, and neuroinflammation while preserving mitochondrial integrity [13]. The neuroprotective properties of coffee have been heavily linked to its high caffeine content, but this has been difficult to demonstrate independently through epidemiological studies due to the confounding effect of other components in caffeinated beverages [9].

2. Effect of Coffee/Caffeine 

Studies by Haller et al. [14][15] showed in early cognitive decline, there is an increase in compensatory basal activity diffused through the posto-temporal region of the brain, which increases the brain’s sensitivity to the neuroprotective action of caffeine [14][15]. Furthermore, MRI studies by Ritchie et al. [16] and Haller et al. [17] showed that caffeine reduces the amount of white matter lesion/cranial volume in cognitively stable elders, contributing to cognitive decline in Dementia/AD [17][18]. Ritchie et al. [18] also showed increased cerebral perfusion in chronic coffee consumers, indicating a possible neuroprotective mechanism of coffee [18]. Moreover, Gelber et al. [19] found high caffeine levels were associated with a lower-odds of having any brain lesion types at autopsy [19]. However, an epidemiological study by Kim et al. [20] did not find any association between coffee intake and hypometabolism, atrophy of AD signature, and WMH volume; instead, it found that coffee exerted a neuroprotective effect by reducing the levels of Aβ [20].

Current literature also seems to support the notion that caffeine/coffee acts as a cognitive normalizer instead of a cognitive enhancer, and as such healthy adults or those with deteriorating cognition receive little benefit from coffee/caffeine treatment [14][15][17][21]. West et al., found that elderly participants with mild cognitive decline showed higher sensitivity to caffeine than healthy younger diabetics [21]. Furthermore, Haller et al., found no changes in neural activation among healthy adults but increased posto-temporal activation in those with MCI, further supporting the notion that caffeine does not act as a cognitive enhancer [15]. Other than that, caffeine/coffee cannot significantly enhance the cognitive function of those suffering from severe cognitive decline [14][17]. Haller et al., showed that caffeine reduces the amount of white matter lesion/cranial volume and increases cerebral perfusion in cognitively stable elders but did not extend the same benefits to elders with deteriorating cognition [17]. Furthermore, Haler et al., in another study used fMRI to study the neural activation induced by caffeine for participants with deteriorating cognition; although this research showed that caffeine reduced cognitive decline in dCON, it did not show the same level of caffeine-induced neural activation in them as seen in those with sCON [14].
The literature also shows that the neuroprotective effect of caffeine/coffee can be confounded by gender, but the evidence is not definitive for either gender, and further research is needed [18][22][23][24]. Two studies (Ritchie et al. [18][23]) only found a statistically significant neuroprotective effect of caffeine among women in the research population but not males [18][23]. Furthermore, Sugiyama et al. [22] found an overall neuroprotective effect of coffee, but this was enhanced among the female cohort and non-smokers and non-drinkers [22]. However, Iranpour et al., in a crude model, found the neuroprotective effect of caffeine extended to both genders, but after adjusting for confounding, found a weak positive correlation for the neuroprotective effect of caffeine only among the males only [24]. The exact mechanism for the difference in neuroprotective properties of caffeine/coffee between gender is unclear and warrants further research; however, it has been hypothesized that this may be due to differences in caffeine metabolism, pharmacodynamics, or hormonal influence [23][24].
Although there is evidence from the clinical studies suggesting that caffeine consumption is protective against AD cognitive decline, further clinical studies are required to prove this link. Ideally, to examine this link, there would need to be an epidemiological study with a large sample size, with multiple surveys collecting extensive data on confounding variables to be adjusted, including data on CYP genotype. The research should also use biological markers (blood tests) to assess caffeine to reduce recall bias, and caffeine data should be collected at multiple points (incl: midlife) during extended follow-up to assess changes in behavior. Furthermore, cognition should also be measured using verified methods, i.e., MMSE, CDR, CERAD, during follow-up. A sub-group should also be randomly chosen and subjected to brain imaging at set intervals during follow-up to identify changes in neural architecture before shifting in behavior. This subgroup should also be subjected to post-mortem analysis to confirm the presence and stage of AD (Figure 1).
/media/item_content/202206/62ac4ce2c3177molecules-27-03737-g001.png
Figure 1. Summary of findings.
This research also analyzed in vivo and in vitro studies that directly examined the relationship between caffeine on AD and cognition, which shows strong evidence that caffeine is neuroprotective against AD through multiple mechanisms. These studies also suggest possible mechanisms of caffeine’s neuroprotective effect. Four of these studies show that caffeine alters APP processing to a non-amyloid pathway, reducing AD burden and cognitive decline [25][26][27][28]. Furthermore, five of these studies show that caffeine‘s neuroprotective effect is due to its ability as a non-selective adenosine receptor antagonist [29][30][31][32][33]. Other than that, studies have also shown that caffeine’s neuroprotective effect is due to its ability to alter protein aggregation [34][35]. The researchers also found evidence that caffeine is able to reduce BNDF levels [36][37]. Caffeine also reduces acetylcholinesterase activity, a mechanism for its neuroprotective effect against AD [38][39]. Some studies showed that the neuroprotective effect of caffeine is by: affecting membrane properties [40], changing GABAergic and glutamatergic neurotransmission [41], reducing endolysosome dysfunction [42], increasing GCSF function [43], and increasing Aβ clearance [44].
Through this research, it's also identified a few in vivo and in vitro studies that were excluded because they did not directly examine the relationship between caffeine and AD. These, however, also posited possible mechanisms of action for the neuroprotective effect of caffeine. Reznikov et al., showed that caffeine significantly enhanced C-Fos expression in the horizontal limb of the diagonal band of Broca [45]. This is thought to explain why AD patients lose their olfactory sense first and that the cognitive enhancing effect of caffeine may be through activation of the basal cholinergic forebrain [45]. Furthermore, Vila-luna et al., showed that the caffeinated group of mice had greater fourth and fifth-order basal dendrites branching in CA1 pyramidal neurons. Laurent et al. showed caffeine’s ability through A2R antagonism/knock out for normalization of hippocampal GSH/GSSG ratio, global reduction in Tau hyperphosphorylation, and neuroinflammatory markers [46].

3. Conclusions

This research found suggestive evidence in clinical studies to propose that caffeine is neuroprotective against dementia and possibly AD, but further studies are required to strengthen this link (Figure 1). It also found strong evidence based on in vivo and in vitro studies that caffeine has some positive effects in AD models, but further studies are warranted to identify all the mechanistic pathways of the neuroprotective effect of caffeine in AD.

References

  1. Scheltens, P.; Blennow, K.; Breteler, M.M.B.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer’s disease. Lancet 2016, 388, 505–517.
  2. Prince, M.J.; Wimo, A.; Guerchet, M.M.; Ali, G.C.; Wu, Y.-T.; Prina, M. World Alzheimer Report 2015—The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends; Alzheimer’s Disease International: London, UK, 2015.
  3. Karran, E.; Mercken, M.; Strooper, B.D. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10, 698–712.
  4. Karch, C.M.; Goate, A.M. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biol. Psychiatry 2015, 77, 43–51.
  5. Arnsten, A.F.T.; Datta, D.; Del Tredici, K.; Braak, H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimer’s Dement. 2021, 17, 115–124.
  6. Genin, E.; Hannequin, D.; Wallon, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Bullido, M.J.; Engelborghs, S.; De Deyn, P.; Berr, C.; et al. APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Mol. Psychiatry 2011, 16, 903–907.
  7. Norton, S.; Matthews, F.E.; Barnes, D.E.; Yaffe, K.; Brayne, C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol. 2014, 13, 788–794.
  8. De Bruijn, R.F.; Bos, M.J.; Portegies, M.L.; Hofman, A.; Franco, O.H.; Koudstaal, P.J.; Ikram, M.A. The potential for prevention of dementia across two decades: The prospective, population-based Rotterdam Study. BMC Med. 2015, 13, 132.
  9. Panza, F.; Solfrizzi, V.; Barulli, M.R.; Bonfiglio, C.; Guerra, V.; Osella, A.; Seripa, D.; Sabba, C.; Pilotto, A.; Logroscino, G. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. J. Nutr. Health Aging 2015, 19, 313–328.
  10. Kim, J.; Lee, K.W. Coffee and Its Active Compounds Are Neuroprotective; Elsevier: Amsterdam, The Netherlands, 2015; pp. 423–427.
  11. Singh, S.S.; Rai, S.N.; Birla, H.; Zahra, W.; Kumar, G.; Gedda, M.R.; Tiwari, N.; Patnaik, R.; Singh, R.K.; Singh, S.P. Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse. Front. Pharm. 2018, 9, 757.
  12. Balakrishnan, R.; Azam, S.; Cho, D.-Y.; Su-Kim, I.; Choi, D.-K. Natural Phytochemicals as Novel Therapeutic Strategies to Prevent and Treat Parkinson’s Disease: Current Knowledge and Future Perspectives. Oxidative Med. Cell. Longev. 2021, 2021, 6680935.
  13. Fahanik-Babaei, J.; Baluchnejadmojarad, T.; Nikbakht, F.; Roghani, M. Trigonelline protects hippocampus against intracerebral Aβ(1–40) as a model of Alzheimer’s disease in the rat: Insights into underlying mechanisms. Metab. Brain Dis. 2019, 34, 191–201.
  14. Haller, S.; Montandon, M.-L.; Rodriguez, C.; Moser, D.; Toma, S.; Hofmeister, J.; Giannakopoulos, P. Caffeine impact on working memory-related network activation patterns in early stages of cognitive decline. Neuroradiology 2017, 59, 387–395.
  15. Haller, S.; Montandon, M.-L.; Rodriguez, C.; Moser, D.; Toma, S.; Hofmeister, J.; Sinanaj, I.; Lovblad, K.-O.; Giannakopoulos, P. Acute Caffeine Administration Effect on Brain Activation Patterns in Mild Cognitive Impairment. J. Alzheimers Dis. 2014, 41, 101–112.
  16. Ritchie, K.; Artero, S.; Portet, F.; Brickman, A.; Muraskin, J.; Beanino, E.; Ancelin, M.-L.; Carriere, I. Caffeine, Cognitive Functioning, and White Matter Lesions in the Elderly: Establishing Causality from Epidemiological Evidence. J. Alzheimers Dis. 2010, 20, S161–S166.
  17. Haller, S.; Montandon, M.-L.; Rodriguez, C.; Herrmann, F.R.; Giannakopoulos, P. Impact of Coffee, Wine, and Chocolate Consumption on Cognitive Outcome and MRI Parameters in Old Age. Nutrients 2018, 10, 1391.
  18. Ritchie, K.; Ancelin, M.L.; Amieva, H.; Rouaud, O.; Carriere, I. The association between caffeine and cognitive decline: Examining alternative causal hypotheses. Int. Psychogeriatr. 2014, 26, 581–590.
  19. Gelber, R.P.; Petrovitch, H.; Masaki, K.H.; Ross, G.W.; White, L.R. Coffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates. J. Alzheimers Dis. 2011, 23, 607–615.
  20. Kim, J.W.; Byun, M.S.; Yi, D.; Lee, J.H.; Jeon, S.Y.; Jung, G.; Lee, H.N.; Sohn, B.K.; Lee, J.-Y.; Kim, Y.K.; et al. Coffee intake and decreased amyloid pathology in human brain. Transl. Psychiatry 2019, 9, 27.
  21. West, R.K.; Ravona-Springer, R.; Livny, A.; Heymann, A.; Shahar, D.; Leroith, D.; Preiss, R.; Zukran, R.; Silverman, J.M.; Schnaider, M. Age Modulates the Association of Caffeine Intake with Cognition and With Gray Matter in Elderly Diabetics. J. Gerontol. Ser. A-Biol. Sci. Med. Sci. 2019, 74, 683–688.
  22. Sugiyama, K.; Tomata, Y.; Kaiho, Y.; Honkura, K.; Sugawara, Y.; Tsuji, I. Association between Coffee Consumption and Incident Risk of Disabling Dementia in Elderly Japanese: The Ohsaki Cohort 2006 Study. J. Alzheimers Dis. 2016, 50, 491–500.
  23. Ritchie, K.; Carriere, I.; de Mendonca, A.; Portet, F.; Dartigues, J.F.; Rouaud, O.; Barberger-Gateau, P.; Ancelin, M.L. The neuroprotective effects of caffeine—A prospective population study (the Three City Study). Neurology 2007, 69, 536–545.
  24. Iranpour, S.; Saadati, H.M.; Koohi, F.; Sabour, S. Association between caffeine intake and cognitive function in adults; effect modification by sex: Data from National Health and Nutrition Examination Survey (NHANES) 2013–2014. Clin. Nutr. 2020, 39, 2158–2168.
  25. Janitschke, D.; Nelke, C.; Lauer, A.A.; Regner, L.; Winkler, J.; Thiel, A.; Grimm, H.S.; Hartmann, T.; Grimm, M.O.W. Effect of Caffeine and Other Methylxanthines on A beta-Homeostasis in SH-SY5Y Cells. Biomolecules 2019, 9, 689.
  26. Arendash, G.W.; Schleif, W.; Rezai-Zadeh, K.; Jackson, E.K.; Zacharia, L.C.; Cracchiolo, J.R.; Shippy, D.; Tan, J. Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 2006, 142, 941–952.
  27. Arendash, G.W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tane, J.; Citron, B.A.; Lin, X.; et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease mice. J. Alzheimers Dis. 2009, 17, 661–680.
  28. Cao, C.; Cirrito, J.R.; Lin, X.; Wang, L.; Verges, D.K.; Dickson, A.; Mamcarz, M.; Zhang, C.; Mori, T.; Arendash, G.W.; et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. J. Alzheimers Dis. 2009, 17, 681–697.
  29. Zhao, Z.A.; Zhao, Y.; Ning, Y.L.; Yang, N.; Peng, Y.; Li, P.; Chen, X.Y.; Liu, D.; Wang, H.; Chen, X.; et al. Adenosine A(2A) receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation. Transl. Psychiatry 2017, 7, e1123.
  30. Bortolotto, J.W.; de Melo, G.M.; Cognato, G.d.P.; Moreira Vianna, M.R.; Bonan, C.D. Modulation of adenosine signaling prevents scopolamine-induced cognitive impairment in zebrafish. Neurobiol. Learn. Mem. 2015, 118, 113–119.
  31. Li, S.; Geiger, N.H.; Soliman, M.L.; Hui, L.; Geiger, J.D.; Chen, X. Caffeine, Through Adenosine A(3) Receptor-Mediated Actions, Suppresses Amyloid-beta Protein Precursor Internalization and Amyloid-beta Generation. J. Alzheimers Dis. 2015, 47, 73–83.
  32. Espinosa, J.; Rocha, A.; Nunes, F.; Costa, M.S.; Schein, V.; Kazlauckas, V.; Kalinine, E.; Souza, D.O.; Cunha, R.A.; Porciuncula, L.O. Caffeine Consumption Prevents Memory Impairment, Neuronal Damage, and Adenosine A(2A) Receptors Upregulation in the Hippocampus of a Rat Model of Sporadic Dementia. J. Alzheimers Dis. 2013, 34, 509–518.
  33. Dall’Igna, O.P.; Fett, P.; Gomes, M.W.; Souza, D.O.; Cunha, R.A.; Lara, D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007, 203, 241–245.
  34. Mancini, R.S.; Wang, Y.; Weaves, D.F. Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation. Front. Neurosci. 2018, 12, 735.
  35. Laurent, C.; Eddarkaoui, S.; Derisbourg, M.; Leboucher, A.; Demeyer, D.; Carrier, S.; Schneider, M.; Hamdane, M.; Müller, C.E.; Buée, L.; et al. Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease-like tau pathology. Neurobiol. Aging 2014, 35, 2079–2090.
  36. Moy, G.A.; McNay, E.C. Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF. Physiol. Behav. 2013, 109, 69–74.
  37. Han, K.; Jia, N.; Li, J.; Yang, L.; Min, L.-Q. Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer’s disease. Mol. Med. Rep. 2013, 8, 737–740.
  38. Mohamed, T.; Osman, W.; Tin, G.; Rao, P.P.N. Selective inhibition of human acetylcholinesterase by xanthine derivatives: In vitro inhibition and molecular modeling investigations. Bioorganic Med. Chem. Lett. 2013, 23, 4336–4341.
  39. Pohanka, M.; Dobes, P. Caffeine Inhibits Acetylcholinesterase, But Not Butyrylcholinesterase. Int. J. Mol. Sci. 2013, 14, 9873–9882.
  40. Gastaldo, I.P.; Himbert, S.; Ram, U.; Rheinstadter, M.C. The Effects of Resveratrol, Caffeine, beta-Carotene, and Epigallocatechin Gallate (EGCG) on Amyloid-beta(25-35) Aggregation in Synthetic Brain Membranes. Mol. Nutr. Food Res. 2020, 64, 2000632.
  41. Zappettini, S.; Faivre, E.; Ghestem, A.; Carrier, S.; Buee, L.; Blum, D.; Esclapez, M.; Bernard, C. Caffeine Consumption during Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. Front. Cell. Neurosci. 2019, 13, 438.
  42. Soliman, M.L.; Geiger, J.D.; Chen, X. Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation. J. Neuroimmune Pharmacol. 2017, 12, 163–170.
  43. Cao, C.; Wang, L.; Lin, X.; Mamcarz, M.; Zhang, C.; Bai, G.; Nong, J.; Sussman, S.; Arendash, G. Caffeine synergizes with another coffee component to increase plasmato cognitive benefits in Alzheimer’s mice. J. Alzheimers Dis. 2011, 25, 323–335.
  44. Qosa, H.; Abuznait, A.H.; Hill, R.A.; Kaddoumi, A. Enhanced Brain Amyloid-β Clearance by Rifampicin and Caffeine as a Possible Protective Mechanism Against Alzheimer’s Disease. J. Alzheimers Dis. 2012, 31, 151–165.
  45. Reznikov, L.R.; Pasumarthi, R.K.; Fadel, J.R. Caffeine elicits c-Fos expression in horizontal diagonal band cholinergic neurons. Neuroreport 2009, 20, 1609–1612.
  46. Laurent, C.; Burnouf, S.; Ferry, B.; Batalha, V.L.; Coelho, J.E.; Baqi, Y.; Malik, E.; Mariciniak, E.; Parrot, S.; Van der Jeugd, A.; et al. A(2A) adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol. Psychiatry 2016, 21, 97–107.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Y Mukish M Yelanchezian
,
Andrea Kwakowsky
,
Henry Waldvogel
,
View Times: 447
Revisions: 3 times (View History)
Update Date: 20 Jun 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback